The Discounted Cash Flow (DCF) valuation of Biomarin Pharmaceutical Inc (BMRN) is 40.13 USD. With the latest stock price at 49.81 USD, the upside of Biomarin Pharmaceutical Inc based on DCF is -19.4%.
Based on the latest price of 49.81 USD and our DCF valuation, Biomarin Pharmaceutical Inc (BMRN) is a sell. selling Biomarin stocks now will result in a potential gain of 19.4%.
| Range | Selected | |
| WACC / Discount Rate | 7.9% - 11.2% | 9.6% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | 29.42 - 70.01 | 40.13 |
| Upside | -40.9% - 40.6% | -19.4% |